Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.

Valerie GlutschFranziska GränJudith WeberAnja GesierichMatthias GoebelerBastian Schilling

Published in: Journal for immunotherapy of cancer (2019)

This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE.

Keyphrases

combination therapy
open label
dna damage
early onset
cell cycle
randomized controlled trial
clinical trial
drug induced
oxidative stress
cell proliferation
study protocol
double blind